Cover Image
Market Research Report
Product code 
365778

Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Drugs In Development, 2021

Published: | Global Markets Direct | 58 Pages | Delivery time: 1-2 business days

Price

Back to Top
Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Drugs In Development, 2021
Published: December 30, 2021
Global Markets Direct
Content info: 58 Pages
Delivery time: 1-2 business days
  • Description
  • Table of Contents
  • List of Tables

Summary:

According to the recently published report 'Leptin Receptor - Drugs In Development, 2021'; Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) pipeline Target constitutes close to 11 molecules.

Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Leptin receptor or LEP-R is a protein encoded by the LEPR gene. It acts as a receptor for hormone LEP/leptin. Upon binding it mediates LEP central and peripheral effects through the activation of different signaling pathways such as JAK2/STAT3 and MAPK cascade. LEP acts as an appetite-regulating factor that induces a decrease in food intake and an increase in energy consumption by inducing anorexinogenic factors and suppressing orexigenic neuropeptides also regulates bone mass and secretion of hypothalamo-pituitary-adrenal hormones. In the periphery increases basal metabolism, influences reproductive function, regulates pancreatic beta-cell function and insulin secretion, is pro-angiogenic and affects innate and adaptive immunity.

The report 'Leptin Receptor - Drugs In Development, 2021' outlays comprehensive information on the Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II and Preclinical stages are 2 and 9 respectively. Report covers products from therapy areas Metabolic Disorders, Oncology, Central Nervous System and Ophthalmology which include indications Obesity, Lipodystrophy (Lipoatrophy), Triple-Negative Breast Cancer (TNBC), Acquired Generalized Lipodystrophy (Lawrence Syndrome), Alzheimer's Disease, Choroidal Neovascularization, Congenital Generalized Lipodystrophy (Berardinelli-Seip Syndrome), Insulin Resistance, Solid Tumor, Type 1 Diabetes (Juvenile Diabetes) and Type 2 Diabetes.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape forLeptin Receptor (HuB219 or OB Receptor or CD295 or LEPR)
  • The report reviews Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) targeted therapeutics

Reasons to Buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4)Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Product Code: GMDHC3037TDB

Table of Contents

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Overview
  • Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Companies Involved in Therapeutics Development
  • Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Drug Profiles
  • Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Dormant Products
  • Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Discontinued Products
  • Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Product Development Milestones
  • Featured News & Press Releases
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

List of Tables

  • Number of Products under Development by Stage of Development, 2021
  • Number of Products under Development by Therapy Areas, 2021
  • Number of Products under Development by Indication, 2021
  • Number of Products under Development by Companies, 2021
  • Products under Development by Companies, 2021
  • Number of Products by Stage and Mechanism of Actions, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Pipeline by Allysta Pharmaceuticals Inc, 2021
  • Pipeline by Amryt Pharma Plc, 2021
  • Pipeline by Arrevus Inc, 2021
  • Pipeline by Astellas Pharma Inc, 2021
  • Pipeline by Cellivery Therapeutics Inc, 2021
  • Pipeline by Jyant Technologies Inc, 2021
  • Pipeline by NeuroNano Pharma Inc, 2021
  • Pipeline by Neurotez Inc, 2021
  • Pipeline by Regeneron Pharmaceuticals Inc, 2021
  • Pipeline by XL-protein GmbH, 2021
  • Dormant Projects, 2021
  • Discontinued Products, 2021

List of Figures

List of Figures

  • Number of Products under Development by Stage of Development, 2021
  • Number of Products under Development by Therapy Areas, 2021
  • Number of Products under Development by Top 10 Indications, 2021
  • Number of Products by Mechanism of Actions, 2021
  • Number of Products by Stage and Mechanism of Actions, 2021
  • Number of Products by Routes of Administration, 2021
  • Number of Products by Stage and Routes of Administration, 2021
  • Number of Products by Molecule Types, 2021
  • Number of Products by Stage and Molecule Types, 2021